ARGX Quote, Financials, Valuation and Earnings

Genfit SA has a net margin of 21.43% compared to argenx SE's net margin of --. argenx SE's return on equity of 21.33% beat Genfit SA's return on equity of --.

argenx SE has a consensus price target of $753.80, signalling upside risk potential of 31.49%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 92.96%. Given that Genfit SA has higher upside potential than argenx SE, analysts believe Genfit SA is more attractive than argenx SE.

argenx SE has a beta of 0.573, which suggesting that the stock is 42.672% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $790.7M, which are larger than Genfit SA quarterly revenues of --. argenx SE's net income of $169.5M is higher than Genfit SA's net income of --. Notably, argenx SE's price-to-earnings ratio is 35.10x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.31x versus 3.13x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of 21.43% compared to argenx SE's net margin of --. argenx SE's return on equity of 21.33% beat NuCana PLC's return on equity of --.

argenx SE has a consensus price target of $753.80, signalling upside risk potential of 31.49%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 294517.56%. Given that NuCana PLC has higher upside potential than argenx SE, analysts believe NuCana PLC is more attractive than argenx SE.

argenx SE has a beta of 0.573, which suggesting that the stock is 42.672% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $790.7M, which are larger than NuCana PLC quarterly revenues of --. argenx SE's net income of $169.5M is higher than NuCana PLC's net income of -$836.1K. Notably, argenx SE's price-to-earnings ratio is 35.10x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.31x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of 21.43% compared to argenx SE's net margin of 37.18%. argenx SE's return on equity of 21.33% beat Novo Nordisk AS's return on equity of 84.88%.

argenx SE has a consensus price target of $753.80, signalling upside risk potential of 31.49%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 25.54%. Given that argenx SE has higher upside potential than Novo Nordisk AS, analysts believe argenx SE is more attractive than Novo Nordisk AS.

argenx SE has a beta of 0.573, which suggesting that the stock is 42.672% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.32% to investors and pays a quarterly dividend of $1.14 per share. argenx SE pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

argenx SE quarterly revenues are $790.7M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. argenx SE's net income of $169.5M is lower than Novo Nordisk AS's net income of $4.1B. Notably, argenx SE's price-to-earnings ratio is 35.10x while Novo Nordisk AS's PE ratio is 21.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.31x versus 7.31x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of 21.43% compared to argenx SE's net margin of -31.41%. argenx SE's return on equity of 21.33% beat Trinity Biotech PLC's return on equity of --.

argenx SE has a consensus price target of $753.80, signalling upside risk potential of 31.49%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2233.54%. Given that Trinity Biotech PLC has higher upside potential than argenx SE, analysts believe Trinity Biotech PLC is more attractive than argenx SE.

argenx SE has a beta of 0.573, which suggesting that the stock is 42.672% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.871%.

argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

argenx SE quarterly revenues are $790.7M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. argenx SE's net income of $169.5M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, argenx SE's price-to-earnings ratio is 35.10x while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.31x versus 0.13x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.